A number of firms have modified their ratings and price targets on shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) recently: 11/11/2015 – BioCryst Pharmaceuticals was downgraded by analysts at Bank of America from a “neutral” rating to an “underperform” rating. 11/10/2015 – BioCryst Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Oppenheimer. 11/6/2015 – […]
